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ABSTRACT
Background In a single general practice (GP) surgery in 
England, there was an eightfold increase in the prevalence 
of type 2 diabetes (T2D) in three decades with 57 cases 
and 472 cases recorded in 1987 and 2018, respectively. 
This mirrors the growing burden of T2D on the health of 
populations round the world along with healthcare funding 
and provision more broadly. Emerging evidence suggests 
beneficial effects of carbohydrate- restricted diets on 
glycaemic control in T2D, but its impact in a ‘real- world’ 
primary care setting has not been fully evaluated.
Methods Advice on a lower carbohydrate diet was offered 
routinely to patients with newly diagnosed and pre- 
existing T2D or prediabetes between 2013 and 2019, in 
the Norwood GP practice with 9800 patients. Conventional 
‘one- to- one’ GP consultations were used, supplemented 
by group consultations, to help patients better understand 
the glycaemic consequences of their dietary choices with 
a particular focus on sugar, carbohydrates and foods with 
a higher Glycaemic Index. Those interested were computer 
coded for ongoing audit to compare ‘baseline’ with ‘latest 
follow- up’ for relevant parameters.
Results By 2019, 128 (27%) of the practice population 
with T2D and 71 people with prediabetes had opted to 
follow a lower carbohydrate diet for a mean duration of 23 
months. For patients with T2D, the median (IQR) weight 
dropped from of 99.7 (86.2, 109.3) kg to 91.4 (79, 101.1) 
kg, p<0.001, while the median (IQR) HbA1c dropped from 
65.5 (55, 82) mmol/mol to 48 (43, 55) mmol/mol, p<0.001. 
For patients with prediabetes, the median (IQR) HbA1c 
dropped from 44 (43, 45) mmol/mol to 39 (38, 41) mmol/
mol, p<0.001. Drug- free T2D remission occurred in 46% 
of participants. In patients with prediabetes, 93% attained 
a normal HbA1c. Since 2015, there has been a relative 
reduction in practice prescribing of drugs for diabetes 
leading to a T2D prescribing budget £50 885 per year less 
than average for the area.
Conclusions This approach to lower carbohydrate 
dietary advice for patients with T2D and prediabetes was 
incorporated successfully into routine primary care over 
6 years. There were statistically significant improvements 
in both groups for weight, HbA1c, lipid profiles and blood 
pressure as well as significant drug budget savings. 
These results suggest a need for more empirical research 
on the effects of lower carbohydrate diet and long- term 
glycaemic control while recording collateral impacts to 
other metabolic health outcomes.
Type 2 diabetes (T2D) is a growing problem 
with an estimated worldwide prevalence 
of 9.3% (463 million people) for 2019.1 In 
the UK, the burden on the National Health 
Service (NHS) is illustrated by the growing 
cost of drugs prescribed for T2D; in 2018, 
these made up 11.4% of total primary care net 
costs and 4.9% of all prescription items.2 In 
the North of England, the Norwood general 
practice (GP) practice, which has been 
serving a stable population of approximately 
9800 patients, experienced an eightfold 
What this paper adds
 ► For those choosing a lower carbohydrate dietary ap-
proach for an average of 23 months it is possible to 
achieve a 46% drug- free T2 diabetes remission rate 
in UK primary care whilst also achieving significant 
improvements in weight, blood pressure and lipid 
profiles.
 ► In patients with prediabetes (HbA1c 42 to 48 mmol/
mol), a LCD approach reduced HbA1c to within a 
non- diabetic threshold in 93% of patients.
 ► Our audit showed participants who started with the 
worst blood sugars (HbA1c) saw the greatest im-
provements in diabetic control.
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increase in T2D cases recorded, rising from 57 in 1987 to 
472 in 2019. This increase in prevalence translates into an 
increased morbidity and mortality for patients, as well as 
increasing pressure on limited healthcare resources.
INTRODUCTION
Several systematic reviews and meta- analyses of 
randomised control trials (RCTs) suggest benefi-
cial effects of carbohydrate- restricted diets in T2D on 
glycaemic control, triglyceride and HDL cholesterol 
profiles.3–5 Between 2018 and 2020, consensus reports by 
the American Diabetes Association (ADA) and the Euro-
pean Association for the Study of Diabetes acknowledged 
low- carbohydrate diets as appropriate dietary options.6 In 
2020, ADA standards of care for T2D report stated: ‘for 
individuals with type 2 diabetes not meeting glycaemic 
targets or for whom reducing glucose- lowering drugs is a 
priority, reducing overall carbohydrate intake with a low- 
carbohydrate or a very- low- carbohydrate eating pattern 
is a viable option’.7 However, there is still some debate 
about sustainability (particularly in terms of long- term 
adherence) and safety of lower carbohydrate diets. For 
example, an RCT comparing a low- carb diet to a low- fat 
diet in people with T2D8 found a similar 3.4% weight 
reduction in both dietary groups and no significant 
change in A1C in either group at 1 year. Also in 2018, the 
British Dietetics Association (BDA) stated: ‘more research 
is needed to ascertain the long- term health impacts of low- 
carbohydrate diets, including on heart health’.9 Beyond 
this uncertainty, little is known about the best methods 
of implementing advice on lower carbohydrate diets in 
primary care practice.
The UK National Institute for Health and Care Excel-
lence T2D guidelines, although not currently advising a 
low- carbohydrate diet specifically, do advise low Glycaemic 
Index (GI) foods as part of the multicomponent manage-
ment of T2D.10 Observations from an earlier service 
improvement pilot at the Norwood surgery suggested 
patients with T2D might achieve a clinically significant 
improvement in glycaemic control by restricting carbohy-
drate intake.11 In addition, dietary carbohydrate restric-
tion may positively benefit other aspects of the metabolic 
syndrome, including central obesity, hypertriglyceri-
daemia and non- alcoholic fatty liver disease.12 13 Encour-
aged by the emerging body of evidence and patient 
demand for more effective lifestyle guidance in T2D, the 
Norwood surgery started routinely offering dietary advice 
on lower carbohydrate diets to all patients with T2D and 
prediabetes from March 2013 to date (September 2020).
The purpose of this secondary analysis of routine 
clinic data was to evaluate the effects of advising a lower 
carbohydrate diet for patients with T2D or prediabetes. 
Specifically, we hoped to answer the following question: 
for those patients choosing a lower carbohydrate diet 
to manage their T2D or prediabetes, when we compare 
‘baseline data’ to ‘latest follow- up’ what are the outcomes 
in terms of body weight, glycaemic control and effect 
on diabetes medication prescribing (British National 
Formulary Chapter 6.1.2.)? Given the BDA concern over 
heart health, additional clinical variables were included 
relating to cardiac risk, namely lipid profile and blood 
pressure (BP). The Diabetes Remission Clinical Trial 
(DiRECT) 14 recently investigated a very- low- calorie diet 
(VLCD) to achieve weight loss and subsequent drug- free 
improvement in T2D, including T2D remission. Raising 
the possibility of T2D remission through dietary inter-
vention has given hope to many people affected by T2D. 
Yet, the exclusion criteria for the DiRECT study included 
patients over 65 years old and patients who have had T2D 
for over 6 years (72 months). We, therefore, decided to 
include analysis of these specific subcohorts in our service 
evaluation.
METHODS
Advice on lowering dietary carbohydrate was offered 
routinely by trained GPs and practice nurses to patients 
with T2D and prediabetes (defined as a haemoglobin 
A1c [HbA1c] from 42 to 48 mmol/mol) from March 
2013 (online supplemental file 1. Low- carb protocol). 
The lower carbohydrate diet was introduced as an option 
alongside clear and simplified explanations of key phys-
iological principles; including how glucose and insulin 
levels change in response to different foods; starchy 
carbohydrates comprise many glucose molecules; and the 
concept that foods can have either a low or high GI and 
glycaemic load (online supplemental file 2).
For patients who opted to try a lower carbohydrate diet, 
dietary advice was given as part of routine GP or prac-
tice nurse consultations. The level of ongoing support 
was tailored to patient choice and clinical need. In addi-
tion to 10 min ‘one- to- one’ appointments (we estimate 
an average of 3 appointments per patient, per year were 
required), the practice offered access to optional 90 min 
evening group sessions that ran approximately once every 
6 weeks. Group sessions included a psychologist who facil-
itated behaviour change by encouraging participants to 
consider their individual health goals, the resources avail-
able to them, setting realistic steps and enabling the indi-
vidual to notice what works for them.15 Patient relatives 
and carers were encouraged to attend as some patients 
relied on others for food shopping or cooking. Group 
sessions also provided a forum for patients to offer prac-
tical support to their peers and for the training of new 
staff. On average, 25 patients attended each session.
Several educational resources were produced to 
support patients and staff. The lower carbohydrate diet 
sheet (figure 1) outlines low GI sources of food in the 
diet. Glycaemic load data, derived from the GI, were 
also presented to encourage a reduction in the intake 
of sugary and starchy foods, for example, sugary break-
fast cereals, rice or potatoes, by replacing them with, for 
example, green leafy vegetables, full- fat dairy, eggs, meat, 
fish, berries and nuts, with sensitivity to each patient’s 
sociocultural dietary needs and preferences. A set of 
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seven broadly indicative infographics were generated, for 
example, figure 2. These help people make wiser dietary 
choices by representing the glycaemic load of example 
food portions alongside an equivalent number of stan-
dard (4 g) teaspoons of table sugar.16 From 2018, staff 
training was formalised through completion of a Royal 
College of General Practitioners e- learning module on 
T2D and the GI, written by one of the authors.17
Our paper is part of an ongoing audit of service provi-
sion. Practice patients who have either T2D or prediabetes 
and choose the low- carb approach are coded within the 
practice computer system. The relevant records can then 
be easily retrieved and interrogated to produce the data 
which is presented as ‘baseline’ (that is before the code 
was put on) and ‘latest follow- up’ (self- explanatory). The 
metrics we measured (weight, BP, lipid profile, HbA1c) 
are part of the routine care for this group of patients at 
the Norwood GP practice. Exclusion criteria were severe 
mental illness, terminal illness and eating disorders. We 
also examined the effects of this intervention in those 
over 65 years and those with T2D for longer than 72 
months. These groups were excluded from the DiRECT 
study.14
Routine clinical data were collected between March 
2013 and March 2019. Baseline measurements of weight 
and BP were done at the surgery and blood tests (HbA1c, 
lipid profiles) by the local NHS phlebotomy clinic. The 
frequency of blood tests depended on clinical need and 
risk assessment as part of standard care. As some patients 
found it challenging to fit fasting blood tests into their 
lifestyle patterns, the results included a greater number 
of incomplete data sets for lipid profiles than other 
measures.
Statistical analyses were performed with R V.3.6.1. 
Summaries of baseline and follow- up data are shown 
as median and the IQR (25th percentile, 75th percen-
tile) for non- normally distributed continuous vari-
ables (age, weight, HbA1c, lipid profile and BP) and 
more normally distributed continuous variables are 
presented as median (SD) (duration of diet). Compar-
isons between baseline and latest follow- up continuous 
variables were made using the Wilcoxon signed rank 
test for paired samples. A p value<0.05 was considered 
statistically significant.
Figure 1 Norwood surgery lower carbohydrate diet sheet.GP, general practice.
Figure 2 Norwood infographic as per it is the glycaemic 
response to, not the carbohydrate content of food that 
matters in diabetes and obesity: The Glycaemic Index 
revisited. Journal of Insulin Resistance 2016.
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Baseline and latest follow- up distributions of patient 
data are presented with box and whisker charts, the box 
represents the median value and the IQR, the red dot 
indicates the mean value and the upper and lower whis-
kers indicate either, the minimum/maximum value, or 
1.5 times the IQR (outliers are not shown).
Data are presented for patients with T2D, and for two 
subgroups: for patients with T2D and aged 65+ years; 
and for patients with T2D having had this diagnosis for 
72 months or longer at the start of the intervention (6 
years). Data are presented for patients with prediabetes 
(HbA1c of 42–47 mmol/mol).
Linear regression models were fitted with HbA1c 
reduction as the outcome and weight loss, age, duration 
of T2D and baseline HbA1C as predictors. The NHS 
in England publishes monthly data about the drugs 
prescribed by every GP in the country. Data on items 
prescribed and costs are processed and organised by GP 
practice and British National Formulary (BNF) chapter 
by the OpenPrescribing website18 These data enable 
analysis comparing prescribing costs in one practice 
(Norwood) to local, regional and national averages. The 
site also generates graphs such as the figure discussed in 
the Results below.
RESULTS
By the end of March 2019, there were 199 patients with 
T2D (N=128) or prediabetes (N=71) who had both 
persisted with the lower carbohydrate programme, and 
for whom service evaluation data had been collected. 
The number of routine (10 min) appointments patients 
attended varied depending partly on risk assessment 
and approximately half of the cohort attended the addi-
tional group sessions on one or more occasion. Table 1 
shows statistical analysis of the cardiometabolic variables 
measured at baseline and the end of the service evalua-
tion period.
At the end of the evaluation period, the Norwood 
GP practice register for T2D had a total of 473 
patients, this cohort of 128 represents 27%. Of these, 
83 (63%) were male, and the mean age was 63 years. 
They were recorded as being on the lower carbohy-
drate programme for a mean (SD) duration of 23 
(16.8) months. For those with T2D, there was a statis-
tically significant reduction in all variables of interest 
other than a statistically significant increase in high 
density lipoprotein (HDL) cholesterol. The most 
prominent changes at the follow- up were a reduction 
in the observed weight from the median (IQR) of 99.7 
(86.2, 109.3) kg to 91.4 (79, 101.1) kg, p<0.001, and 
for HbA1c from the median (IQR) of 65.5 (55, 82) 
mmol/mol to 48 (43, 55) mmol/mol, p<0.001 (table 1 
and figure 3). Overall, 121 of the 128 patients (94.4%) 
lost weight. Seven patients either lost no weight or 
gained weight, yet these seven individuals had a mean 
improvement in HbA1c of 21.1 mmol/mol, similar to 
the average for the whole group. Regression analysis 
showed little overall relationship between the magni-
tude of weight loss (predictor) and improvement 
in HbA1c (outcome), R2=0.0058, p=0.402, β=0.234 
mmol/mol/kg, (95% CI: −0.317 to 0.785) (online 
supplemental file 3). Table 1 and figure 4 demonstrate 
the significant reduction in total and LDL choles-
terol, triglycerides and total/HDL cholesterol ratio 
and a significant increase in HDL cholesterol seen in 
patients with T2D. A median reduction in systolic and 
diastolic BP occurred of 11 and 5.1 mm Hg, respec-
tively, p<0.001.
Medication use: 40 of the T2D participants were newly 
diagnosed with diabetes and so not on any medications 
for T2D at baseline. There were a further 34 participants 
with more established diabetes managed by diet alone. 
Metformin was started in just four of these patients. The 
remaining 54 people were on medication for T2D at 
baseline. Twenty- nine medications were stopped in this 
group, sometimes more than one drug in any particular 
patient. As a result of this 19 of the 54 patients previously 
on medication became medication free, making a total 
of 89 people with T2D managed without medication at 
latest follow- up (table 2.) Of these, 59 were both free of 
medication and had an HbA1c<48 mmol/mol.
Figure 5 demonstrates that the Norwood GP prac-
tice had the lowest prescribing costs for antidiabetic 
medications (BNF 6.1.2) in the local area. According to 
OpenPrescribing. net, by April 2020, Norwood spent £50 
885 less per year than is average for the area. Further 
interrogation of this resource, looking at overall prac-
tice prescribing for T2D against regional and national 
figures, indicates a 35% increase in Norwood prescribing 
compared with a 53% rise in the local area for the 5 years 
from March 2015 (online supplemental file 4).
Figure 6 shows regression analysis of the improve-
ment in HbA1c with respect to baseline HbA1c on the 
programme for the entire T2D cohort. It shows a positive 
relationship (R2 0.752, p<0.001, β=0.806, 95% CI: 0.724 
to 0.888) between higher initial HbA1c (worse diabetic 
control) and greater improvements in diabetic control on 
the programme. A subcohort of interest to clinicians is 
patients with poor glycaemic control. Of the 128 partic-
ipants, 40 patients had a baseline HbA1c of 80 mmol/
mol or greater (mean 97.3 mmol/mol). The average 
reduction in HbA1c for this subcohort was 41.9 mmol/
mol, more than double the overall average improvement. 
The average HbA1c of this group at latest follow- up had 
improved to 55.4 mmol/mol. Regarding medications 
in this subcohort who started with very poor diabetic 
control; two patients were started on metformin, and the 
following medications were deprescribed in five patients; 
metformin in two, gliclazide in three, liraglutide in one 
and insulin in one.
Analysis of the results from the two subcohorts of 
interest (time since diagnosis of diabetes and age) is 
shown separately in table 1. There was the same trend 
in cardiometabolic variables that occurred in the entire 
cohort. The results for these subcohorts are:
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In the 45 patients with T2D for over 72 months at the 
introduction to this service, the median (IQR) weight 
reduced from 96.2 (86.2, 106.0) kg to 86.9 (76.9, 95.4) 
kg, p<0.001, and median (IQR) HbA1c reduced from 73 
(62, 84) mmol/mol to 49 (45, 56) mmol/mol, p<0.001. 
Regression analysis showed little overall relationship 
between the duration of diabetes at initiation of the 
programme (predictor) and improvement in HbA1c 
(outcome) for the main T2D cohort (n=127), R2=0.007, 
p=0.348, β=0.025 mmol/mol/month (95% CI: −0.027 to 
0.076) (online supplemental file 5).
Of the 53 patients over 65 years old with T2D at the 
introduction to this service, 11 were over 80 years old, 
and the average age was 75 years. Median (IQR) weight 
Table 1 Statistical analysis of cardiometabolic variables measured at baseline and at the end of service evaluation period
Baseline measure Latest follow up P value Matched pairs n (%)
Cohort of 128 patients with T2D. Mean (SD) duration of diet 23 (16.8) months
  Age (years) 63 (54, 73) – – –
  Weight (Kg) 99.7 (86.2, 109.3) 91.4 (79, 101.1) <0.001 124 (96.9)
  HbA1c (mmol/mol) 65.5 (55, 82) 48 (43, 55) <0.001 127 (99)
  Serum cholesterol (mmol/L) 4.9 (4.1, 5.7) 4.4 (3.8, 5.0) <0.001 83 (64.8)
  HDL cholesterol (mmol/L) 1.2 (1.0, 1.3) 1.3 (1.0, 1.5) <0.001 96 (75.0)
  Chol/HDL ratio 4.0(3.0,5.1) 3.7(2.9,4.4) <0.001 83(64.8)
  Triglyceride (mmol/L) 2.6 (1.6, 3.2) 1.7 (1.0, 2.1) <0.001 85 (66.4)
  Systolic BP (mmHg) 144 (135, 151) 133 (126, 140) <0.001 95 (74.2)
  Diastolic BP (mmHg) 83.1 (78, 90) 78 (70, 82) <0.001 95 (74.2)
Sub–cohort of 45 patients with T2D diagnosed >72 months before introduction to this service
  Age (years) 67 (57, 75) – – –
  Weight (Kg) 96.2 (86.2, 106.0) 86.9 (76.9, 95.4) <0.001 44 (97.8)
  HbA1c (mmol/mol) 73 (62, 84) 49 (45, 56) <0.001 45 (100)
  Serum cholesterol (mmol/L) 4.6 (3.9, 5.1) 4.2 (3.6, 4.6 0.01 31 (68.9)
  HDL cholesterol (mmol/L) 1.1 (0.8, 1.4) 1.2 (1.0, 1.4) 0.039 35 (77.8)
  Triglyceride (mmol/L) 2.8 (1.7, 3.2) 1.7 (1.1, 2.2) <0.001 34 (75.6)
  Systolic BP (mmHg) 138 (130, 141) 131 (122, 139) 0.004 30 (66.7)
  Diastolic BP in mmHg 79 (76, 80) 76 (70, 80) 0.053 30 (66.7)
Sub–cohort of 53 patients with T2D, aged 65 or older at the introduction to this service
  Age (years) 75 (70, 80) – – –
  Weight (Kg) 91.8 (81.3, 100.8) 83.3 (74, 91.8) <0.001 50 (94.3)
  HbA1c (mmol/mol) 64 (56, 80) 49 (45, 56) <0.001 53 (100)
  Serum cholesterol (mmol/l) 4.7 (4.0, 5.5) 4.4 (3.6, 4.9) 0.011 31 (58.6)
  HDL cholesterol (mmol/L) 1.3 (1.0, 1.4) 1.3 (1.1, 1.4) 0.446 38 (71.7)
  Triglyceride in (mmol/L) 2.4 (1.6, 3.0) 1.6 (1.0, 2.2) <0.001 36 (67.9)
  Systolic BP (mmHg) 143 (132, 150) 134 (129, 140) <0.001 38 (71.7)
  Diastolic BP (mmHg) 80 (76, 80) 76 (70, 80) 0.033 38 (71.7)
Cohort of 71 people with Prediabetes Mean (SD) duration of diet 22 (17.4) months
  Age (years) 65 (59, 73) – – –
  Weight (Kg) 90.6 (78.0, 99.0) 82.2 (71.8, 89.6) <0.001 71 (100)
  HbA1c (mmol/mol) 44 (43, 45) 39 (38, 41) <0.001 70 (98.5)
  Serum cholesterol (mmol/L) 5.4 (4.6, 6.0) 5.1 (4.3, 5.6) 0.008 49 (72.1)
  HDL cholesterol (mmol/L) 1.3 (1.1, 1.5) 1.4 (1.2, 1.6) 0.010 49 (72.1)
  Triglyceride (mmol/L) 1.9 (1.2, 2.4) 1.2 (0.7, 1.5) <0.001 33 (48.5)
  Systolic BP (mmHg) 141 (130, 151) 131 (124, 138) <0.001 51 (75.0)
  Diastolic BP (mmHg) 83 (78, 90) 77 (72, 80) <0.001 51 (75.0)
The results shown as median (IQR) unless otherwise stated.
BP, blood pressure; T2D, type 2 diabetes.
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reduced from 91.8 (81.3, 100.8) kg at baseline to 83.3 (74, 
91.8) kg, p<0.001, while median (IQR) HbA1c changed 
from 64 (56, 80) mmol/mol to 49 (45, 56) mmol/mol, 
p<0.001. Regression analysis showed little overall rela-
tionship between age at initiation of the programme 
(predictor) and improvement in HbA1c (outcome) for 
the main T2D cohort (n=127), R2=0.0019, p=0.626, β 
0.068 mmol/mol/year (95% CI: −0209 to 0.346) (online 
supplemental file 6).
The 71 patients with prediabetes represent 11.1% 
of the 637 people on the practice prediabetes register, 
35 (49%) were male, and the mean age was 65 (59,73) 
years. They were recorded as being on a lower carbohy-
drate diet for a mean (SD) duration of 22 (17.4) months. 
The most prominent changes were observed for median 
(IQR) weight, which reduced from 90.6 (78.0, 99.0) kg to 
82.2 (71.8, 89.6) kg, p<0.001, and median (IQR) HbA1c, 
which reduced from 44 (43, 45) mmol/mol to 39 (38, 41) 
mmol/mol, p<0.001 (table 1 and figure 7). By the end 
of the service evaluation, 66 (93%) had a normal HbA1c 
(<42 mmol/mol). Statistically significant changes to lipid 
profiles and BP in patients with prediabetes followed the 
same pattern as described in patients with T2D.
DISCUSSION
Analysis of our data shows significant improvements in 
all the metrics evaluated (HbA1c, weight, BP and lipid 
profiles) for the 27% of the practice T2D population 
who chose the approach. However, the methodological 
limitations of this service evaluation must be considered 
in the interpretation of these results. Our audit reports 
results from people who chose to take up this interven-
tion and who persisted with it. It is a practice- based service 
evaluation not a prospective research study so lack of 
randomisation introduces the possibility of selection bias. 
The absence of a control group also means we cannot 
compare the dietary intervention directly with routine 
care. However, some idea of the results one might expect 
from routine care can be drawn from the control arm of 
the DiRECT study, discussed below.19 Lack of randomi-
sation also risks confounding. For example, individuals 
who chose the diet may have other unique characteristics 
or behaviours that confer benefit. Co- intervention bias 
is another possibility, where for example other medica-
tions or exercise recommendations may have conferred 
benefit that were not included in the analysis. Despite 
this, the wide IQR of baseline HbA1c (55–82 mmol/mol) 
and an overall average of 65 mmol/mol (suggesting rela-
tively poor glycaemic control) indicates that a ‘real- world’ 
cross section of patients was included. Another limitation 
is relying on the patients’ word regarding adherence to a 
lower carbohydrate diet; hence, we must acknowledge the 
risk of reporting bias. Although the average weight loss of 
8.3 kg does suggest significant dietary change, we cannot 
know with any certainty what has actually happened to 
the balance of the different macronutrients in the diet 
of the participants. Another limitation concerns the 
teaspoon of sugar infographics used in figure 2, based on 
the glycaemic load. It is important to note that this info-
graphic is indicative only and does not represent the true 
process of glucose metabolism.20
For several years, a ‘low- carbohydrate diet’ has gener-
ally been accepted to be one containing less than 130 g 
of carbohydrate per day.13 But in routine care, it may not 
be realistic for patients to count grams of carbohydrate 
on a regular basis. Our data suggest a more simple and 
practical approach to lowering dietary carbohydrate can 
be associated with significant improvements in HbA1c, 
weight, lipid profiles and BP without the need for precise 
daily carbohydrate or calorie counting. Patients appear 
to have benefited from having received clear and simpli-
fied explanations of how sugar and carbohydrates affect 
blood glucose levels and how to recognise foods with high 
glycaemic loads, as illustrated by infographics (figure 2), 
in addition to individualised follow- up and multidis-
ciplinary group sessions. In clinical practice, avoiding 
in- depth discussions around portion sizes and carbo-
hydrate counting has been patient friendly and time 
efficient.
Of all the patients with T2D at the Norwood GP prac-
tice, 27% adopted a lower carbohydrate diet during this 
service evaluation period. The approach was not adopted 
by all patients, which is a reminder of the importance 
of individual choice in diet and lifestyle matters. The 
same might also be said for healthcare professionals as 
the level of interest, commitment and confidence in this 
dietary approach to T2D varied between the 10 clinicians 
Figure 3 Type 2 diabetes box and whisker plots; baseline 
and latest follow- up haemoglobin A1c (HbA1c) and weight.
Figure 4 Box and whisker type 2 diabetes; baseline and 
latest follow- up lipid results.
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involved at the GP practice, especially at the begin-
ning. Still, the number of patients adopting this dietary 
approach has continued to rise and, as of August 2020, 
the cohort includes 173 patients with T2D, representing 
36% of the practice total.
In our practice, the idea of drug- free remission of T2D 
has inspired many patients and clinicians. However, at 
the time of writing there is no internationally agreed defi-
nition of T2D remission. The criteria used at Norwood 
and suggested by Taylor et al21 are a previous diagnosis 
of type 2 diabetes by WHO criteria and an HbA1c<6.5% 
(48 mmol/mol) without antidiabetic medication. Using 
this definition, the DiRECT study14 showed that a VLCD 
of <800 calories per day can lead to weight loss and drug- 
free T2D remission in a UK primary care setting. At 12 
months, T2D remission was achieved in 68 of 149 partic-
ipants giving a remission rate of 46%. When followed up 
further, at 24 months, the remission rate had dropped to 
36%.19 At Norwood, 59 of 128 patients receiving lower 
carbohydrate dietary advice achieved drug- free T2D 
remission, giving a rate of 46% at 23 months duration 
of the approach. As a comparison to illustrate how rare 
remission is in usual care DiRECT quotes a remission 
rate at 24 months of just 2% for routine T2D care in the 
UK, emphasising the potential value in novel dietary 
approaches to this problem. The DiRECT study excluded 
patients who, at recruitment, had been diagnosed with 
T2D for longer than 72 months or were over 65 years 
old. In our practice, this would have excluded 45 and 53 
patients, respectively. Of the over 65- year- old patients at 
Norwood, 11 were over 80 years, the oldest was 91 years 
old. The average improvement in HbA1c for this group 
was 15 mmol/mol. Similarly, in those patients with T2D 
for over 72 months, the average reduction in HbA1c 
was 24 mmol/mol, demonstrating a significant improve-
ment. As shown in the results above our findings suggest 
both older people and those who had had diabetes for 
longer had good outcomes on a lower carbohydrate diet. 
Table 2 Breakdown of the number of people with T2D who were medication free at latest follow- up
Baseline status
Drugs for diabetes*
added +
stopped−
Number of people medication free at 
latest follow- up
Newly diagnosed T2D, n=40 0 40
Diet- controlled T2D, n=34 Metformin +4 30
T2D on medication, n=54 Gliclazide −12 19
Metformin −8
Insulin −4
Dapagliflozin −2
Sitagliptin −2
Liraglutide −1
Total=128 −25 89
*Also, Insulin doses were halved in four patients.
T2D, type 2 diabetes.
Figure 5 Data from: OpenPrescribing.net, EBM DataLab, 
University of Oxford, 2020, accessed July 2020. Prescribing 
of drugs for diabetes British National Formulary (BNF) 6.1.2 
for all the general practice (GP) practices in Southport and 
Formby Clinical Commisioning Group (CCG).
Figure 6 Initial HbA1c versus improvement in HbA1c for 
127 patients with type 2 diabetes on a low- carb diet for an 
average of 23 months.
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Looking at the overall cohort with diabetes, we found 
very little relationship between duration of diabetes or 
age of participant at baseline and decrease in HbA1c 
(online supplemental files 5 and 6). It may be unfortu-
nate to exclude these subgroups from similar avenues of 
research in the future.
Patients whose T2D is poorly controlled, for example, 
with HbA1c of 80 mmol/mol and more, may present the 
clinician with a dilemma as the risks might be considered 
so high that medication ought to be started or increased 
immediately. In this service evaluation, 40 patients 
presented with an HbA1c over 80 mmol/mol. Of those, 
the highest was 144 mmol/mol. These 40 patients ulti-
mately achieved an average improvement in HbA1c of 
41.9 mmol/mol, meaning the best results from this project 
were achieved in patients who presented with the worst 
glycaemic control. Figure 6 demonstrates graphically 
the clear positive relationship between a higher initial 
HbA1c and the degree of improvement in HbA1c that 
was observed on our programme. This suggests it may be 
a reasonable approach (particularly if the patient hopes 
to avoid medication) to offer a trial of advice on a lower 
carbohydrate diet with appropriate clinical monitoring to 
patients with particularly high HbA1c levels as an alter-
native to immediately starting medications. An important 
caveat is that closer monitoring of weight, blood glucose 
and HbA1c was needed. For this group we were encour-
aging self- testing for blood glucose, reweighing every 2 
weeks and repeating blood tests in 6 weeks.
Weight loss has been assumed to be a key determinant 
of the reduction in HbA1c in T2D population. Surpris-
ingly in this service evaluation, there was a weak and 
statistically non- significant relationship between weight 
loss and HbA1C reduction as shown by regression anal-
ysis (online supplemental file 3.) Small numbers of those 
whose weight remained stable or whose weight increased 
over time also achieved a reduction in HbA1C. It is 
possible that other mechanisms beyond weight loss and 
associated improvement in insulin sensitivity mediate the 
effects of lower carbohydrate diet on glycaemic control. 
For example, in bariatric surgery, significant improve-
ments are often seen in the first week after surgery, before 
substantial weight loss has occurred.22
We saw two particular cases where patients had signif-
icant weight loss that was not matched by improve-
ments in HbA1c. In one case, the patient had, in fact, 
developed type 1 diabetes and needed insulin. Further 
investigation into the other case led to the diagnosis of 
a hidden malignancy. Another pattern is where both 
weight and HbA1c rose together, on direct questioning 
this typically represented higher GI carbohydrate foods 
‘creeping’ back into the diet. This prompted the clini-
cian to support the patient back to a lower carbohydrate 
diet. Our impression is that group sessions were partic-
ularly helpful in this scenario as participants did not 
require an appointment so could access support easily 
and out of working hours. Quality long- term support is 
vital to achieving sustained benefits from any approach 
to managing people with T2D, a point reinforced by the 
decline in T2D remission rate seen in the DiRECT study 
follow- up over time.19 A recent, randomised controlled 
feasibility study demonstrated it is practical for prac-
tice nurses to provide follow- up support as part a low- 
carbohydrate dietary intervention for patients with T2D 
in a UK primary care setting.23
The lower carbohydrate diet option also appeared to 
be both an acceptable and effective intervention to the 
71 participants with prediabetes (HbA1c from 42 to 48 
mmol/mol). After an average duration of 22 months, 
only five still had an HbA1c of 42 mmol/mol or above. 
This ‘prediabetes remission rate’ of 93% may provide a 
further message of hope. In clinical practice, it is encour-
aging for patients to hear that nearly all who choose a 
lower carbohydrate diet may see their prediabetes resolve 
alongside additional improvements in weight, BP and 
lipid profiles. One notable example of an additional 
benefit is the improvements seen in serum triglycerides 
of about 30% (table 1 and figure 4). It is currently chal-
lenging for a clinician to know what to suggest when faced 
with a patient with high triglycerides and obesity. A lower 
carbohydrate diet may well have a role in this group too 
and should prompt further research.
In discussions around low- carbohydrate diets, the 
potential replacement of dietary carbohydrate for fat was 
a cause for concern around any impact on cardiovascular 
outcomes. In general, with respect to lipid profiles our 
findings support the meta- analysis by Gjuladin- Hellon et 
al4 who concluded ‘large randomised controlled trials 
of at least 6 months duration with carbohydrate restric-
tion appear superior in improving lipid markers when 
compared with low- fat diets’. Given the improved average 
HbA1c, lipid profiles, weight and BP, we are optimistic of 
improved cardiovascular risk for our cohort.
For clinicians considering advising a lower carbohy-
drate diet for patients who are already on antidiabetic 
medications, there are three important considerations:
1. Whether the drug/diet combination poses a risk of hy-
poglycaemia. Insulin is an obvious culprit for this as 
are some oral agents such as gliclazide. Careful mea-
surement of blood glucose, dose reduction and/or ces-
sation of culprit drugs is crucial to patient safety.
Figure 7 Prediabetes box and whisker plots; baseline and 
latest follow- up HbA1c and weight.
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2. Sodium- glucose co- transporter-2 (SGLT2) inhibitor 
drugs, combined with a low- carbohydrate diet, have 
the potential to lead to diabetic ketoacidosis that may 
be masked by relative normoglycaemia. This class of 
drugs ought to be avoided in this context.
3. As demonstrated in our service evaluation data and 
elsewhere,24 lowering carbohydrate in the diet is asso-
ciated with a lowering of BP. For patients already on 
antihypertensive medication, this can lead to symp-
tomatic hypotension requiring dose reduction and/or 
cessation of culprit drugs.
Prescribing T2D medication in the context of a 
carbohydrate- restricted diet was the subject of a useful 
British Journal of General Practice review25 that states the diet 
is safe with metformin, the most commonly prescribed 
antidiabetic medication. In addition to deprescribing 
antidiabetic medications analysis from the Norwood GP 
practice on hypertension, published separately,24 shows 
that 20% of the antihypertensive drugs were also stopped 
due to significant improvements in BP.
Finally, over the last 5 years, there has been a relative reduc-
tion in antidiabetic medications prescribed by Norwood 
against local, regional and national figures (see OpenPre-
scribing data in online supplemental file 1). We cannot prove 
this low- carb approach is the cause of this reduction but 
believe factors involved are; deprescribing in patients with 
T2D and a reduction in the need to prescribe new antidia-
betic drugs for patients with improved glycaemic control on 
a lower carbohydrate diet. Also, given the option, no patient 
with T2D chose to start medication before first trying the 
lower carbohydrate diet. Indeed, only four T2D patients were 
started on antidiabetic medications during the period and 
only after diet and lifestyle measures had been tried without 
success. Importantly between 2013 and 2019, none of the 
cohort with prediabetes developed T2D or needed drugs for 
diabetes.
Nationally, prescribing rates for T2D are a huge strain on 
the NHS budget. In the financial year 2017/2018, there were 
53.4 million items prescribed for diabetes at a total net ingre-
dient cost of £1012.4 million,2 up by £421.7 million since 
2007/2008. As outlined in the results above, compared with 
the 17 GP practices in the Southport and Formby region, the 
Norwood GP practice spend on antidiabetic medication is 
£50 885 per year less than the average for the area (figure 5). 
It is likely that the reduction in antihypertensive drugs will 
add to the savings which are welcome, considering the extra 
costs of this service were approximately £9000 per year.16
CONCLUSION
This service evaluation found that advising a lower carbohy-
drate diet approach for patients with T2D and prediabetes 
can be effectively incorporated into routine primary care 
over a prolonged period (6 years). The basic model centred 
on the assumption that, for these individuals, glycaemic 
control (as measured by HbA1c) is most influenced by 
the consumption of food with higher GI and glycaemic 
loads, such as those containing simple sugars and starchy 
carbohydrates. Advice was given to lower the amount of these 
food supported by illustrative infographics. Follow- up largely 
consisted of regular 10 min appointments with optional 
group sessions. The role of group sessions was to reinforce 
diet and lifestyle change, particularly to help ‘rescue’ patients 
who were struggling to maintain dietary changes. Significant 
improvements were observed across all cardiometabolic 
parameters measured: weight, HbA1c, lipid profile and BP 
with drug- free T2D remission in 46% of all patients with T2D. 
Of the prediabetic patients, 93% attained a normal HbA1c 
and similar improvements in cardiometabolic markers as 
seen in the diabetic cohort. Additional benefits included 
deprescribing of antidiabetic medications and significant 
prescribing budget savings.
Due to the practice- specific nature of this evaluation, there 
is limited external validity. Still, these results could form the 
basis for similar service improvement projects in primary 
care. Similar pilots could be designed to test the validity and 
cost- savings of this approach. At the very least, for patients, 
clinicians and others affected by T2D and prediabetes, the 
results might provide hope of better health outcomes in the 
future. These results highlight a need for more empirical 
research on the effects of lower carbohydrate diets and long- 
term glycaemic control while recording collateral impacts to 
other metabolic health outcomes.
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